Related Experiment Video
Updated: Feb 22, 2026
11:06
Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Published on: January 31, 2022
5.4K
The Low-Dose (7.5 mg/day) Pioglitazone Therapy.
Hidekatsu Yanai1, Hiroki Adachi1
1Department of Internal Medicine, National Center for Global Health and Medicine Kohnodai Hospital, Chiba, Japan.
Journal of Clinical Medicine Research
|September 16, 2017
Summary
Low-dose pioglitazone may offer similar metabolic benefits to higher doses with fewer side effects. This approach could improve glucose and lipid metabolism while reducing risks of weight gain, edema, and heart failure.
Area of Science:
- Pharmacology
- Endocrinology
- Metabolic Diseases
Background:
- Pioglitazone, a thiazolidinedione, activates PPAR-gamma, enhancing insulin sensitivity and improving glucose/lipid metabolism.
- Previous studies indicate pioglitazone reduces major adverse cardiovascular events and all-cause mortality in diabetic patients.
- However, higher doses are linked to increased risks of heart failure, fractures, edema, and weight gain.
Purpose of the Study:
- To evaluate the efficacy and safety of low-dose (7.5 mg/day) pioglitazone therapy.
- To compare the dose-response of pioglitazone's beneficial and adverse effects across different daily dosages (7.5 mg, 15 mg, 30 mg).
Main Methods:
- Systematic review and meta-analysis of existing reports.
- Focused search on studies examining daily doses of 7.5 mg, 15 mg, and/or 30 mg of pioglitazone.
- Dose-response analysis of pioglitazone's effects on metabolic parameters and adverse events.
Main Results:
- Low-dose pioglitazone (7.5 mg/day) may achieve comparable improvements in glucose/lipid metabolism, fatty liver, insulin resistance, and adiponectin levels as standard and high doses.
- Low-dose therapy is potentially associated with a reduced incidence of weight gain, edema, and heart failure compared to higher doses.
Conclusions:
- Low-dose pioglitazone therapy presents a potentially favorable risk-benefit profile.
- This dosage may offer effective metabolic improvements with a lower risk of adverse effects, warranting further clinical consideration.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
720
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
720
01:06Oral Hypoglycemic Agents: Glinides
744
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
744
01:23Dipeptidyl Peptidase 4 Inhibitors
759
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
759
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
621
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
621
01:16Insulin: Dosing Regimen and Adverse Effects
887
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
887
01:17Oral Hypoglycemic Agents: Sulfonylureas
1.3K
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.3K